In SLE, earlier longitudinal studies demonstrated that inhibiting BAFF using belimumab selectively reduced the total number of transitional and naïve B cells with no effects on memory B cells [15]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.